CEL-SCI Completes Key Step In Preparation For Phase III Trial
This content is restricted. The full version of this content is available for VaBio members only.
CEL-SCI Corporation (NYSE AMEX: CVM), based in Vienna, Virginia, has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer. The drug was filled in CEL-SCI’s state-of-the-art “Cold-Fill” manufacturing facility, located outside of Baltimore, which has been designed to fill [...]